고분자 Drug Discovery 아웃소싱 시장 규모, 점유율 및 동향 분석 보고서 : 워크플로우별, 서비스별, 치료 영역별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Large Molecule Drug Discovery Outsourcing Market Summary

The global large molecule drug discovery outsourcing market size was estimated at USD 3.1 billion in 2025 and is projected to reach USD 6.5 billion by 2033, growing at a CAGR of 9.7% from 2026 to 2033. The market growth is driven by increased demand for biologics, growing pipeline complexity, the use of AI discovery platforms, and greater reliance on CRO expertise.

Furthermore, cost efficiency, shorter time-to-market, improvements in high-throughput screening, and protein engineering are likely to support expansion in the large molecule drug discovery industry. Pharmaceutical companies are increasingly shifting their focus from small molecules to larger biomolecules, including peptides, recombinant proteins, and gene-modifying agents, driven by rising demand for biologics. As a result, drug sponsors are actively seeking the services of contract research organizations (CROs) that specialize in drug discovery tailored to these biologics. This trend has led to a rise in outsourcing strategies that emphasize early-phase scientific collaboration and expertise in areas such as bioassay development, structural biology, and functional screening.

Furthermore, emerging trends highlight strategic partnerships between biopharma companies and CROs that focus on innovative platform-based models, which help mitigate R&D risks while accelerating the advancement of assets. In addition, the demand for outsourcing services is impacted by the depth of scientific expertise, cost-effectiveness, and specialization in therapeutic areas. This has led to increased demand for collaboration with partners with a strong focus on neurodegenerative diseases, rare disorders, and autoimmune conditions.

Moreover, the global expansion of the market is transforming the landscape, as companies seek biologics innovation hubs in regions like North America and the Asia Pacific. In addition, CROs are integrating AI-driven tools, biomarker discovery platforms, and automated screening processes to enhance the accuracy of candidate selection. This combination of scientific advancement, geographic expansion, and digital innovation is establishing large-molecule drug discovery outsourcing as a fundamental aspect of modern biologics R&D strategies. These factors are expected to drive market growth over the forecast period.

Global Large Molecule Drug Discovery Outsourcing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global large molecule drug discovery outsourcing market report based on the workflow, service, therapeutic area, end use, and region.

• Workflow Outlook (Revenue, USD Million, 2021 - 2033)
• Target Identification & Screening
• Target Validation & Functional Informatics
• Lead Identification & Candidate Optimization
• Preclinical Development
• Others
• Service Outlook (Revenue, USD Million, 2021 - 2033)
• Chemistry Services
• Biology Services
• Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
• Respiratory system
• Pain and Anesthesia
• Oncology
• Ophthalmology
• Hematology
• Cardiovascular
• Endocrine
• Gastrointestinal
• Immunomodulation
• Anti-infective
• Central Nervous System
• Dermatology
• Genitourinary System
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical & Biotechnology companies
• Academic Institutes
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait
  • Qatar
  • Oman

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Workflow
  • 1.2.2. Service
  • 1.2.3. Therapeutic Area
  • 1.2.4. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Top-Down Analysis
  • 1.7.3. Bottom-Up Approach
  • 1.7.4. Multivariate Analysis
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Large Molecule Drug Discovery Outsourcing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising Demand for Biologics and Biosimilars
    • 3.2.1.2. Increasing R&D Complexity Driving Outsourcing Adoption
    • 3.2.1.3. Advancements in AI and High-Throughput Technologies
    • 3.2.1.4. Cost and Time Efficiency Through CRO Partnerships
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Data Security and Intellectual Property Concerns
    • 3.2.2.2. Regulatory and Compliance Challenges
• 3.3. Technology Landscape
• 3.4. Pricing Model Analysis
• 3.5. Tariff Impact Analysis
• 3.6. Value Chain Analysis
  • 3.6.1. Supply Trends
  • 3.6.2. Demand Trends
• 3.7. Market Analysis Tools
  • 3.7.1. Porter's Five Force Analysis
  • 3.7.2. PESTEL by SWOT Analysis

Chapter 4. Large Molecule Drug Discovery Outsourcing Market: Workflow Estimates & Trend Analysis

• 4.1. Large Molecule Drug Discovery Outsourcing Market Workflow Outlook (Revenue in USD Million, 2021 - 2033): Segment Dashboard
• 4.2. Large Molecule Drug Discovery Outsourcing Market Workflow Outlook (Revenue in USD Million, 2021 - 2033): Movement Analysis
• 4.3. Large Molecule Drug Discovery Outsourcing Market Estimates & Forecasts, By Workflow, 2021 - 2033 (USD Million)
• 4.4. Target Identification & Screening
  • 4.4.1. Target Identification & Screening Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Target Validation & Functional Informatics
  • 4.5.1. Target Validation & Functional Informatics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Lead Identification & Candidate Optimization
  • 4.6.1. Lead Identification & Candidate Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Preclinical Development
  • 4.7.1. Preclinical Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.8. Others
  • 4.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Large Molecule Drug Discovery Outsourcing Market: Service Estimates & Trend Analysis

• 5.1. Large Molecule Drug Discovery Outsourcing Market Service Outlook (Revenue in USD Million, 2021 - 2033): Segment Dashboard
• 5.2. Large Molecule Drug Discovery Outsourcing Market Service Outlook (Revenue in USD Million, 2021 - 2033): Movement Analysis
• 5.3. Large Molecule Drug Discovery Outsourcing Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)
• 5.4. Chemistry Services
  • 5.4.1. Chemistry Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Biology Services
  • 5.5.1. Biology Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Large Molecule Drug Discovery Outsourcing Market: Therapeutic Area Estimates & Trend Analysis

• 6.1. Large Molecule Drug Discovery Outsourcing Market, By Therapeutic Area: Segment Dashboard
• 6.2. Large Molecule Drug Discovery Outsourcing Market, By Therapeutic Area: Movement Analysis
• 6.3. Large Molecule Drug Discovery Outsourcing Market Estimates & Forecasts, By Therapeutic Area, 2021 - 2033 (USD Million)
• 6.4. Respiratory system
  • 6.4.1. Respiratory system Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Pain and Anesthesia
  • 6.5.1. Pain and Anesthesia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Oncology
  • 6.6.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Ophthalmology
  • 6.7.1. Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Hematology
  • 6.8.1. Hematology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.9. Cardiovascular
  • 6.9.1. Cardiovascular Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.10. Endocrine
  • 6.10.1. Endocrine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.11. Gastrointestinal
  • 6.11.1. Gastrointestinal Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.12. Immunomodulation
  • 6.12.1. Immunomodulation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.13. Anti-infective
  • 6.13.1. Anti-infective Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.14. Central Nervous System
  • 6.14.1. Central Nervous System Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.15. Dermatology
  • 6.15.1. Dermatology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.16. Genitourinary System
  • 6.16.1. Genitourinary System Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Large Molecule Drug Discovery Outsourcing Market: End Use Estimates & Trend Analysis

• 7.1. Large Molecule Drug Discovery Outsourcing Market End Use Outlook (Revenue in USD Million, 2021 - 2033): Segment Dashboard
• 7.2. Large Molecule Drug Discovery Outsourcing Market End Use Outlook (Revenue in USD Million, 2021 - 2033): Movement Analysis
• 7.3. Large Molecule Drug Discovery Outsourcing Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million)
• 7.4. Pharmaceutical & Biotechnology companies
  • 7.4.1. Pharmaceutical & Biotechnology companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Academic Institutes
  • 7.5.1. Academic Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Large Molecule Drug Discovery Outsourcing Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Dashboard
• 8.2. Regional Market Share Analysis, 2025 & 2033
• 8.3. North America
  • 8.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.2. U.S
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.3. Canada
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.4. Mexico
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.4. Europe
  • 8.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.2. UK
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. Germany
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.4. France
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.5. Italy
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.6. Spain
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.7. Denmark
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.8. Sweden
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Competitive Scenario
    • 8.4.8.3. Regulatory Framework
    • 8.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.9. Norway
    • 8.4.9.1. Key Country Dynamics
    • 8.4.9.2. Competitive Scenario
    • 8.4.9.3. Regulatory Framework
    • 8.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. Japan
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. China
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. India
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. Thailand
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.6. South Korea
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.7. Australia
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Latin America
  • 8.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. Brazil
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. Argentina
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. MEA
  • 8.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. South Africa
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. Saudi Arabia
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.4. UAE
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Competitive Scenario
    • 8.7.4.3. Regulatory Framework
    • 8.7.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.5. Kuwait
    • 8.7.5.1. Key Country Dynamics
    • 8.7.5.2. Competitive Scenario
    • 8.7.5.3. Regulatory Framework
    • 8.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.6. Oman
    • 8.7.6.1. Key Country Dynamics
    • 8.7.6.2. Competitive Scenario
    • 8.7.6.3. Regulatory Framework
    • 8.7.6.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.7. Qatar
    • 8.7.7.1. Key Country Dynamics
    • 8.7.7.2. Competitive Scenario
    • 8.7.7.3. Regulatory Framework
    • 8.7.7.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Key Participant Categorization
  • 9.1.1. Market Leaders
  • 9.1.2. Emerging Players
• 9.2. Market Share/Assessment Analysis, 2025 (Heat Map Analysis)
• 9.3. Company Profiles
  • 9.3.1. Evotec SE
    • 9.3.1.1. Company Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Service Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Charles River Laboratories International, Inc.
    • 9.3.2.1. Company Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Service Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. WuXi AppTec
    • 9.3.3.1. Company Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Service Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. Laboratory Corporation of America Holdings
    • 9.3.4.1. Company Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Service Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. Pharmaceutical Product Development, LLC
    • 9.3.5.1. Company Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Service Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. Merck & Co., Inc.
    • 9.3.6.1. Company Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Service Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. GenScript Biotech Corporation
    • 9.3.7.1. Company Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Service Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. Jubilant Biosys Limited
    • 9.3.8.1. Company Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Service Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. Pharmaron Beijing Co., Ltd.
    • 9.3.9.1. Company Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Service Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. Syngene International Limited
    • 9.3.10.1. Company Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Service Benchmarking
    • 9.3.10.4. Strategic Initiatives
  • 9.3.11. Dalton Pharma Services
    • 9.3.11.1. Company Overview
    • 9.3.11.2. Financial Performance
    • 9.3.11.3. Service Benchmarking
    • 9.3.11.4. Strategic Initiatives
  • 9.3.12. Domainex Ltd.
    • 9.3.12.1. Company Overview
    • 9.3.12.2. Financial Performance
    • 9.3.12.3. Service Benchmarking
    • 9.3.12.4. Strategic Initiatives
  • 9.3.13. Eurofins Scientific SE
    • 9.3.13.1. Company Overview
    • 9.3.13.2. Financial Performance
    • 9.3.13.3. Service Benchmarking
    • 9.3.13.4. Strategic Initiatives
  • 9.3.14. QIAGEN N.V.
    • 9.3.14.1. Company Overview
    • 9.3.14.2. Financial Performance
    • 9.3.14.3. Service Benchmarking
    • 9.3.14.4. Strategic Initiatives
  • 9.3.15. TCG Lifesciences Pvt Ltd.
    • 9.3.15.1. Company Overview
    • 9.3.15.2. Financial Performance
    • 9.3.15.3. Service Benchmarking
    • 9.3.15.4. Strategic Initiatives